

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/240042 A1

- (51) **International Patent Classification:**
A61K 39/00 (2006.01) *C12N 15/113* (2010.01)
- (21) **International Application Number:**
PCT/US2023/067936
- (22) **International Filing Date:**
05 June 2023 (05.06.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/349,286 06 June 2022 (06.06.2022) US
63/379,564 14 October 2022 (14.10.2022) US
- (71) **Applicant: CARIBOU BIOSCIENCES, INC.** [US/US];
2929 7th Street, Suite 105, Berkeley, CA 94710 (US).
- (72) **Inventors: KANNER, Steven, B.;** 610 S Van Ness Avenue,
Unit 1, Los Angeles, CA 90005 (US). **KWONG, George;**
1386 South Blaney Avenue, San Jose, CA 95129 (US).
- (74) **Agent: ZIMMERMAN, Olga;** Director, I.P., Caribou Bio-
sciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA
94710 (US).

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

(54) **Title:** TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS




FIG. 1

(57) **Abstract:** The invention comprises methods and compositions for treating autoimmune diseases with engineered immune cells including cytotoxic T cells and natural killer (NK) cells. The engineered immune cells comprise a chimeric antigen receptor (CAR). Methods of making the engineered cells, methods of administration and treatment regimens are also disclosed.



WO 2023/240042 A1